Published online before print February 24, 2005, doi: 10.1161/01.ATV.0000160342.20342.00
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 American Heart Association, Inc.
Atherosclerosis and Lipoproteins |
Plasma Levels of Soluble Receptor for Advanced Glycation End Products and Coronary Artery Disease in Nondiabetic Men
From the Department of Cardiology (C.F., M.P.B., C.B.), the Molecular Medicine Laboratory (E.E.), the Department of Internal Medicine and Medical Therapeutics (A.D., D.G.), University Hospital IRCCS San Matteo, Italy; and the Department of Genetics and Microbiology (M.C.), University of Pavia, Pavia, Italy.
Correspondence to Colomba Falcone, MD, Department of Cardiology, University Hospital IRCCS San Matteo, University of Pavia, Piazzale Golgi 2, 27100, Pavia, Italy. E-mail c.falcone{at}smatteo.pv.it
Objective— The receptor for advanced glycation end products (RAGE) is a cell surface receptor whose signaling pathway has been implicated in atherogenesis. RAGE has an endogenous secretory receptor form, called soluble RAGE (sRAGE), that could exert antiatherogenic effects by acting as a decoy. We sought to determine whether a decreased plasma level of sRAGE could be independently associated with the prevalence of coronary artery disease (CAD) in nondiabetic men.
Methods and Results— Plasma levels of sRAGE were determined in 328 nondiabetic male patients with angiographically proved CAD and in 328 age-matched healthy controls. The concentration of sRAGE in plasma was significantly lower (P<0.0001) in CAD cases [median (interquartile range): 966 (658–1372) pg/mL] than in control subjects [1335 (936–1954) pg/mL]. In logistic regression analysis, the multivariate-adjusted odds ratio for the presence of CAD was 6.719 (95% confidence interval, 3.773 to 11.964; P<0.0001) when the lowest quartile of the sRAGE level was compared with the highest quartile.
Conclusions— Our findings indicate that low levels of sRAGE in plasma are independently associated with the presence of CAD in nondiabetic men and suggest that sRAGE is one of the clinically important molecules associated with atherosclerosis.
Soluble RAGE could prevent the adverse effects of RAGE signaling by acting as a decoy. We found that low levels of sRAGE in plasma are independently associated with the presence of CAD in nondiabetic men. These findings suggest that sRAGE is one of the clinically important molecules associated with atherosclerosis.
Key Words: coronary artery disease • risk factor • soluble receptor for advanced glycation end products
Related Article:
Arterioscler Thromb Vasc Biol 2005 25: 879-882.
This article has been cited by other articles:
 |
|
 |
|
  H. Maillard-Lefebvre, E. Boulanger, M. Daroux, C. Gaxatte, B. I. Hudson, and M. Lambert Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases Rheumatology, October 1, 2009; 48(10): 1190 - 1196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Buhimschi, M. A. Baumbusch, A. T. Dulay, E. A. Oliver, S. Lee, G. Zhao, V. Bhandari, R. A. Ehrenkranz, C. P. Weiner, J. A. Madri, et al. Characterization of RAGE, HMGB1, and S100{beta} in Inflammation-Induced Preterm Birth and Fetal Tissue Injury Am. J. Pathol., September 1, 2009; 175(3): 958 - 975. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Lindsey, J. A. de Lemos, F. Cipollone, C. R. Ayers, A. Rohatgi, D. A. Morrow, A. Khera, and D. K. McGuire Association Between Circulating Soluble Receptor for Advanced Glycation End Products and Atherosclerosis: Observations from the Dallas Heart Study Diabetes Care, July 1, 2009; 32(7): 1218 - 1220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Pullerits, H. F. d'Elia, A. Tarkowski, and H. Carlsten The decrease of soluble RAGE levels in rheumatoid arthritis patients following hormone replacement therapy is associated with increased bone mineral density and diminished bone/cartilage turnover: a randomized controlled trial Rheumatology, July 1, 2009; 48(7): 785 - 790. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Z. Kalea, N. Reiniger, H. Yang, M. Arriero, A. M. Schmidt, and B. I. Hudson Alternative splicing of the murine receptor for advanced glycation end-products (RAGE) gene FASEB J, June 1, 2009; 23(6): 1766 - 1774. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Sun, T. Ishida, T. Yasuda, Y. Kojima, T. Honjo, Y. Yamamoto, H. Yamamoto, S. Ishibashi, K.-i. Hirata, and Y. Hayashi RAGE mediates oxidized LDL-induced pro-inflammatory effects and atherosclerosis in non-diabetic LDL receptor-deficient mice Cardiovasc Res, May 1, 2009; 82(2): 371 - 381. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B Lindsey, F. Cipollone, S. M Abdullah, and D. K Mcguire Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications Diabetes and Vascular Disease Research, January 1, 2009; 6(1): 7 - 14. [Abstract] [PDF]
|
|
|
|
 |
|
 C S Calfee, L B Ware, M D Eisner, P E Parsons, B T Thompson, N Wickersham, M A Matthay, and the NHLBI ARDS Network Plasma receptor for advanced glycation end products and clinical outcomes in acute lung injury Thorax, December 1, 2008; 63(12): 1083 - 1089. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. L. Nienhuis, K. de Leeuw, J. Bijzet, A. Smit, C. G. Schalkwijk, R. Graaff, C. G. Kallenberg, and M. Bijl Skin autofluorescence is increased in systemic lupus erythematosus but is not reflected by elevated plasma levels of advanced glycation endproducts Rheumatology, October 1, 2008; 47(10): 1554 - 1558. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Katakami, M. Matsuhisa, H. Kaneto, T.-A. Matsuoka, K. Sakamoto, T. Yasuda, and Y. Yamasaki Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in type 1 diabetes patients Diabetes and Vascular Disease Research, September 1, 2008; 5(3): 190 - 197. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Montaner, M. Perea-Gainza, P. Delgado, M. Ribo, P. Chacon, A. Rosell, M. Quintana, M. E. Palacios, C. A. Molina, and J. Alvarez-Sabin Etiologic Diagnosis of Ischemic Stroke Subtypes With Plasma Biomarkers Stroke, August 1, 2008; 39(8): 2280 - 2287. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z Sternberg, B Weinstock-Guttman, D Hojnacki, P Zamboni, R Zivadinov, K Chadha, A Lieberman, L Kazim, A Drake, P Rocco, et al. Soluble receptor for advanced glycation end products in multiple sclerosis: A potential marker of disease severity Multiple Sclerosis, July 1, 2008; 14(6): 759 - 763. [Abstract] [PDF]
|
|
|
|
|
|
B. I. Hudson, A. M. Carter, E. Harja, A. Z. Kalea, M. Arriero, H. Yang, P. J. Grant, and A. M. Schmidt Identification, classification, and expression of RAGE gene splice variants FASEB J, May 1, 2008; 22(5): 1572 - 1580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kalousova, M. Jachymova, O. Mestek, M. Hodkova, M. Kazderova, V. Tesar, and T. Zima Receptor for advanced glycation end products--soluble form and gene polymorphisms in chronic haemodialysis patients Nephrol. Dial. Transplant., July 1, 2007; 22(7): 2020 - 2026. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Koyama, T. Shoji, S. Fukumoto, K. Shinohara, T. Shoji, M. Emoto, K. Mori, H. Tahara, E. Ishimura, R. Kakiya, et al. Low Circulating Endogenous Secretory Receptor for AGEs Predicts Cardiovascular Mortality in Patients With End-Stage Renal Disease Arterioscler Thromb Vasc Biol, January 1, 2007; 27(1): 147 - 153. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Basta, A. M. Sironi, G. Lazzerini, S. Del Turco, E. Buzzigoli, A. Casolaro, A. Natali, E. Ferrannini, and A. Gastaldelli Circulating Soluble Receptor for Advanced Glycation End Products Is Inversely Associated with Glycemic Control and S100A12 Protein J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4628 - 4634. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Shoji, H. Koyama, T. Morioka, S. Tanaka, A. Kizu, K. Motoyama, K. Mori, S. Fukumoto, A. Shioi, N. Shimogaito, et al. Receptor for advanced glycation end products is involved in impaired angiogenic response in diabetes. Diabetes, August 1, 2006; 55(8): 2245 - 2255. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Koyama, T. Shoji, H. Yokoyama, K. Motoyama, K. Mori, S. Fukumoto, M. Emoto, T. Shoji, H. Tamei, H. Matsuki, et al. Plasma Level of Endogenous Secretory RAGE Is Associated With Components of the Metabolic Syndrome and Atherosclerosis Arterioscler Thromb Vasc Biol, December 1, 2005; 25(12): 2587 - 2593. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Emanuele, A. D'Angelo, C. Tomaino, G. Binetti, R. Ghidoni, P. Politi, L. Bernardi, R. Maletta, A. C. Bruni, and D. Geroldi Circulating Levels of Soluble Receptor for Advanced Glycation End Products in Alzheimer Disease and Vascular Dementia Arch Neurol, November 1, 2005; 62(11): 1734 - 1736. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. I. Hudson, E. Harja, B. Moser, and A. M. Schmidt Soluble Levels of Receptor for Advanced Glycation Endproducts (sRAGE) and Coronary Artery Disease: The Next C-Reactive Protein? Arterioscler Thromb Vasc Biol, May 1, 2005; 25(5): 879 - 882. [Full Text] [PDF]
|
|